Chinese glucose monitor maker Sinocare (SZ:300298) and a sovereign wealth fund there are said to be in the hunt for the diabetes business Johnson & Johnson (NYSE:JNJ) is looking to unload.
The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, Animas and Calibra Medical diabetes businesses and later elected to shutter the Animas insulin pump subsidiary.
Get the full story at our sister site, Drug Delivery Business News.
The post Report: Chinese bidders eye Johnson & Johnson’s diabetes biz appeared first on MassDevice.
from MassDevice http://ift.tt/2DjYJR5
Cap comentari:
Publica un comentari a l'entrada